000135966 001__ 135966
000135966 005__ 20240229105049.0
000135966 0247_ $$2doi$$a10.1002/ijc.31322
000135966 0247_ $$2pmid$$apmid:29479701
000135966 0247_ $$2ISSN$$a0020-7136
000135966 0247_ $$2ISSN$$a1097-0215
000135966 037__ $$aDKFZ-2018-00703
000135966 041__ $$aeng
000135966 082__ $$a610
000135966 1001_ $$0P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aPulte, Dianne$$b0$$eFirst author$$udkfz
000135966 245__ $$aSurvival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century.
000135966 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000135966 3367_ $$2DRIVER$$aarticle
000135966 3367_ $$2DataCite$$aOutput Types/Journal article
000135966 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1554293479_19925
000135966 3367_ $$2BibTeX$$aARTICLE
000135966 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000135966 3367_ $$00$$2EndNote$$aJournal Article
000135966 520__ $$aHepatobiliary tract cancers (HBTCs) are a heterogeneous group of cancers with high mortality. Because most of these cancers, with the exception of hepatocellular carcinoma (HCC), are rare, few data are available concerning the population level survival expectations of patients with HBTC. Here, we describe survival of patients with HBTC in Germany with comparison to survival in the US. Therefore, data were extracted from 12 databases in Germany and the Surveillance, Epidemiology and End Results (SEER13) database in the US. Period analysis and modeled period analysis were used to calculate 5-year relative survival estimates for patients with HBTC diagnosed from 1997 to 2013. HCC was the most common HBTC in each database, accounting for over 1/3 of HBTC in Germany and about half of cases in the US. Overall age adjusted 5-year relative survival for HBTC in 2006-2013 was 19.1% in Germany and 20.6% in the US. Five-year relative survival increased by 3.8% units in Germany and 4.5% units in the US between 2002-2005 and 2010-2013. Five-year relative survival for individual types of HBTC ranged from 9.8% in Germany and 2.9% in the US for not otherwise specified biliary tract cancers to 44.4% and 50.1%, respectively, in Germany and the US for duodenal cancers. In conclusion, survival for HBTC remains poor in both Germany and the US, although a small increase in survival in the past decade was observed. Further work to find better treatment options for HBTC is needed to improve survival.
000135966 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000135966 588__ $$aDataset connected to CrossRef, PubMed,
000135966 7001_ $$00000-0003-0404-7394$$aWeberpals, Janick$$b1
000135966 7001_ $$0P:(DE-HGF)0$$aSchröder, Chloé Charlotte$$b2
000135966 7001_ $$aEmrich, Katharina$$b3
000135966 7001_ $$aHolleczek, Bernd$$b4
000135966 7001_ $$aKatalinic, Alexander$$b5
000135966 7001_ $$aLuttmann, Sabine$$b6
000135966 7001_ $$aSirri, Eunice$$b7
000135966 7001_ $$00000-0001-8004-4940$$aJansen, Lina$$b8
000135966 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$udkfz
000135966 7001_ $$aGroup, GEKID Cancer Survival Working$$b10$$eCollaboration Author
000135966 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31322$$gVol. 143, no. 2, p. 324 - 332$$n2$$p324 - 332$$tInternational journal of cancer$$v143$$x0020-7136$$y2018
000135966 909CO $$ooai:inrepo02.dkfz.de:135966$$pVDB
000135966 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000135966 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-0404-7394$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000135966 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000135966 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-8004-4940$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000135966 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000135966 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000135966 9141_ $$y2018
000135966 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000135966 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000135966 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000135966 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000135966 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000135966 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000135966 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000135966 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000135966 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000135966 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000135966 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000135966 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000135966 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000135966 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000135966 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000135966 980__ $$ajournal
000135966 980__ $$aVDB
000135966 980__ $$aI:(DE-He78)C070-20160331
000135966 980__ $$aI:(DE-He78)G110-20160331
000135966 980__ $$aI:(DE-He78)L101-20160331
000135966 980__ $$aUNRESTRICTED